Donor Dendritische Cellen vaccinatie bij hematologische maligne aandoeninge
- Conditions
- ow grade, intermediate and high grade non Hodgkin lymphoma (NHL), M.Hodgkin, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplasia (MDS).Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2012-002435-28-NL
- Lead Sponsor
- niversity Medical Center Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Patients with low grade, intermediate and high grade non Hodgkin lymphoma (NHL), M.Hodgkin, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplasia (MDS) and proven residual disease (including as determined by disease specific of patient specific PCR) minimally 6 months after Allogeneic Stem Cell transplantation (Allo-SCT) and subsequent persistent disease after a first pre-emptive DLI or patients with relapsed haematological disease after Allo-SCT and persistent disease after a first therapeutic DLI.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10
1. WHO performance 3-4
2. Presence of severe cardiac hepatic, renal, metabolic disease
3. Rapidly progressive disease
4. No measurable disease
5. Life expectancy > 3 months
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method